Key result
LDLR splice variant rs72658867-A is linked to ~24% lower CAD risk and reduced non-HDL cholesterol.
Why the study?
The genetic variants in LDLR that affect non-HDL cholesterol levels and coronary artery disease risk were not fully characterized, especially non-coding low frequency variants.
Do LDLR splice region variants rs72658867-A and rs17248748-T lower non-HDL-C and protect against CAD?
Observational (n=269,344)
Yes
Do LDLR splice region variants rs72658867-A and rs17248748-T lower non-HDL-C and protect against CAD?
Odds Ratio: 0.76
p-value: p=2.7 × 10^-8
Sequence variants that disrupt the LDL receptor, such as rs72658867-A, can lower non-HDL-C and protect against coronary artery disease.
Low-frequency LDLR variants may refine CAD risk models; extends known signals but leaves open validation and clinical adoption.
Through high coverage whole-genome sequencing and imputation of the identified variants into a large fraction of the Icelandic population, we found four independent signals in the low density lipoprotein receptor gene (LDLR) that associate with levels of non-high density lipoprotein cholesterol (non-HDL-C) and coronary artery disease (CAD). Two signals are novel with respect to association with non-HDL-C and are represented by non-coding low frequency variants (between 2-4% frequency), the splice region variant rs72658867-A in intron 14 and rs17248748-T in intron one. These two novel associations were replicated in three additional populations. Both variants lower non-HDL-C levels (rs72658867-A, non-HDL-C effect = -0.44 mmol/l, Padj = 1.1 × 10⁻⁸⁰ and rs17248748-T, non-HDL-C effect = -0.13 mmol/l, Padj = 1.3 × 10⁻¹²) and confer protection against CAD (rs72658867-A, OR = 0.76 and Padj = 2.7 × 10⁻⁸ and rs17248748-T, OR = 0.92 and Padj = 0.022). The LDLR splice region variant, rs72658867-A, located at position +5 in intron 14 (NM_000527:c.2140+5G>A), causes retention of intron 14 during transcription and is expected to produce a truncated LDL receptor lacking domains essential for function of the receptor. About half of the transcripts generated from chromosomes carrying rs72658867-A are characterized by this retention of the intron. The same variant also increases LDLR mRNA expression, however, the wild type transcripts do not exceed levels in non-carriers. This demonstrates that sequence variants that disrupt the LDL receptor can lower non-HDL-C and protect against CAD.
No takes yet. Share an insight, caveat, or question.
Grétarsdóttir et al. (2015) conducted an observational in Coronary Artery Disease (n=269,344). LDLR splice region variant rs72658867-A vs. Non-carriers (reference allele) was evaluated on Coronary artery disease (OR 0.76, p=2.7 × 10^-8). The LDLR splice region variant rs72658867-A lowers non-HDL cholesterol by 0.44 mmol/l and reduces the risk of coronary artery disease (OR 0.76) in the general population.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: